Serina Therapeutics

Serina Therapeutics Advancing polymer science with POZ™, our next-gen biocompatible technology, built to optimize small molecule therapeutics.

06/02/2026

The 505(b)(2) NDA pathway leverages existing clinical data to reduce development risk, shorten timelines, and bring improved therapies to patients more efficiently.

05/21/2026

Serina’s story began in Huntsville, Alabama, and grew alongside the world-class scientific ecosystem surrounding the HudsonAlpha Institute for Biotechnology, proving that breakthrough innovation is driven by talent, not geography.

05/15/2026

At Serina, we are excited to be in a pivotal stage of development, advancing from platform validation toward meaningful clinical and strategic milestones. Backed by long-term partners and focused on disciplined ex*****on, we continue to advance our clinical programs and build value across our broader platform.

05/04/2026

Serina is developing SER-252, a POZ-enabled form of apomorphine designed to address the limits of short half-life and inconsistent drug levels in advanced Parkinson’s disease. By enabling a steady, controlled release within the therapeutic window, this approach improves how the drug performs in the body while using the 505(b)(2) NDA pathway to advance development more efficiently.

04/30/2026

Advancing medicine isn’t always about discovering new molecules, it’s about improving how known therapies perform in the body. Serina’s approach to drug development focuses on optimizing well-characterized molecules using its POZ platform. By extending half-life, enhancing stability, and enabling controlled, sustained release, POZ allows therapies to maintain more consistent exposure within the therapeutic window, addressing limitations that have historically restricted clinical performance.

04/20/2026

Serina’s patient-focused approach aligns with the FDA’s evolving priority to accelerate therapies for areas of high unmet need. By leveraging a well-characterized molecule and a differentiated delivery platform, Serina is advancing a more efficient, data-driven path to bring meaningful treatment options to patients with advanced Parkinson’s disease.

02/09/2026

Momentum in Development
Serina moves forward with SER-252 following FDA clearance, supporting continued progress toward clinical evaluation in advanced Parkinson’s disease.

01/21/2026

Serina was founded by scientists with decades of experience across drug development and biotechnology innovation. With deep expertise spanning medicinal and organic chemistry, polymer science, and clinical translation, the team set out to address a long-standing challenge in medicine: how to extend the lifespan and improve the performance of small-molecule therapies. This vision led to the creation of the POZ platform: a proprietary polymer technology designed to enhance stability, bioavailability, and therapeutic consistency. Today, this scientific foundation continues to guide Serina’s strategy and ex*****on, attracting respected advisors and collaborators who recognize the breakthrough potential of POZ-enabled therapies. Each program advances with the confidence that comes from scientific credibility, proven track records, and an unwavering focus on meaningful patient outcomes.

10/21/2025

How the FDA alignment helps Serina
Serina’s approach focuses on reformulating well-established small molecules into improved, patient-friendly therapies. By building on known drugs rather than starting from scratch, the team minimizes clinical risk, shortens development timelines, and creates a pipeline of treatments designed to enhance quality of life for patients worldwide.

Address

601 Genome Way, Suite 2001
Huntsville, AL
35806

Telephone

+12563279630

Website

Alerts

Be the first to know and let us send you an email when Serina Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category